Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma, Inc. reported net revenues of $194.5 million for the three months ended March 31, 2026, up from strong growth in Attruby and Beyonttra sales, including $180.6 million of net product revenue.
The company recorded a net loss attributable to common stockholders of $164.0 million, or $0.84 per share, as it continues to invest heavily in research and development and selling, general and administrative activities. Operating cash outflow was $197.3 million, but BridgeBio ended the quarter with $879.9 million in cash and cash equivalents and $60.3 million in marketable securities.
BridgeBio issued $632.5 million of 0.75% Convertible Senior Notes due 2033, using part of the proceeds to repurchase common stock and positioning itself to address existing convertible notes. The company also submitted a New Drug Application for oral BBP-418 for LGMD2I/R9 and continues late-stage development of low-dose infigratinib and encaleret.
BridgeBio Pharma reported strong first-quarter 2026 growth while remaining unprofitable and launched a major buyback. Total revenue reached $194.5 million, up from $116.6 million a year earlier, driven by $180.6 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA in Europe and Japan.
Total operating costs and expenses rose to $300.5 million as the company invested in Attruby commercialization and late-stage pipeline programs, leading to a net loss of $166.6 million, or $0.84 per share, similar to the prior year. Cash, cash equivalents, and marketable securities were $940.2 million as of March 31, 2026, bolstered by new convertible note financing.
The board approved a stock repurchase program of up to $500 million of common stock, which can be executed over time at management’s discretion. BridgeBio highlighted real-world and clinical data supporting Attruby, reported an NDA submission for BBP‑418 in LGMD2I/R9, and outlined plans to file NDAs for encaleret and oral infigratinib in 2026, positioning three programs for potential launches in 2026–2027.
BridgeBio Pharma’s Chief Accounting Officer, Apuli Maricel, sold shares under a pre-set trading plan. On April 30, 2026, Maricel executed an open-market sale of 2,000 shares of Common Stock at $71.58 per share. After this transaction, Maricel directly holds 134,115 shares. The sale was made pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025, indicating it was pre-arranged rather than timed spontaneously.
BridgeBio Pharma, Inc. will hold its 2026 annual stockholders meeting virtually on June 22, 2026, to vote on key governance and compensation items. Stockholders of record at the close of business on April 23, 2026, when 195,806,242 common shares were outstanding, may vote.
Proposals include electing three Class I directors, advisory votes on executive pay and the frequency of future say‑on‑pay votes, ratifying Deloitte & Touche LLP as auditor for 2026, and approving an amendment to the 2021 Stock Option and Incentive Plan to add 2,000,000 reserved shares. Director Randal W. Scott will not stand for re‑election, and the board size will be reduced from 14 to 13.
The company highlights a pay‑for‑performance philosophy: in 2025, 93% of CEO pay and 88% of CFO pay were at risk via bonuses and equity, and performance stock units and a stock ownership policy were added after prior say‑on‑pay support of about 75% and investor feedback.
BridgeBio Pharma reports beneficial ownership by Neil Kumar of 9,282,982 shares of Common Stock. That ownership represents 4.6% of the class based on 195,707,702 shares outstanding as of March 31, 2026. The filing breaks the total into direct holdings, exercisable options, restricted stock units vesting within 60 days, and shares held in trusts.
The filing lists 3,903,183 options exercisable within 60 days and 71,215 RSUs vesting within 60 days, plus trust-held shares totaling 5,074,133 that give shared voting/dispositive power.
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported that entities associated with him sold a total of 80,000 shares of Common Stock of BBIO in open‑market transactions on April 9–10, 2026. The trades were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co‑trustee, at prices in the mid‑$70s per share.
The filing states these sales were made under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and includes a disclaimer that Kumar does not admit beneficial ownership of the trust shares beyond any pecuniary interest. After the transactions, the trusts and Kumar’s direct account together still hold several million shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed sales of 120,000 shares of Common Stock (Conversion Management Incentive Units) dated 03/26/2026. The filing also lists multiple 10b5-1 sales by related trusts and an individual totaling several recent transactions, including a 28,053-share sale on 02/19/2026. Shares outstanding were 193,862,871 as of 04/09/2026.
Viking Global Investors and related entities report beneficial ownership of 11,842,434 shares of BridgeBio Pharma, Inc. common stock, representing 6.1% of the class. This percentage is based on 193,862,871 shares outstanding as of February 12, 2026. The filing is Amendment No. 11 to a Schedule 13D and is primarily being made to remove former advisory director David C. Ott as a reporting person after his March 31, 2026 retirement, after which he is no longer a beneficial owner of the reported shares. The amendment restates the current group of reporting persons, describes their control structure, and notes that, other than transactions listed in Exhibit 99.13, no additional trades have occurred since the prior amendment.
BridgeBio Pharma submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing is supported by the Phase 3 FORTIFY trial’s 12‑month interim analysis, which met all pre‑specified primary and secondary endpoints.
Interim data showed rapid, consistent treatment effects, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio expects, if approved, a potential U.S. launch in late 2026 or early 2027 and notes BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially any form of limb-girdle muscular dystrophy.